Table_3_EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs.docx

The prevalence and impact of epidermal growth factor receptor (EGFR) Q787Q polymorphism on the treatment of lung adenocarcinoma remains unclear. We retrospectively analyzed patients with stage IV lung adenocarcinoma to evaluate the prevalence of the EGFR Q787Q polymorphism and its influence on effects of tyrosine kinase inhibitor (TKI) treatment. A total of 333 patients were included in this study. The prevalence of the EGFR Q787Q polymorphism was 38%, 42%, and 35% in the total patients, EGFR mutation negative, and EGFR mutation positive groups, respectively. The prevalence of EGFR Q787Q polymorphism was significantly higher in EGFR wild-type patients than in the general non-cancerous population from Taiwan Biobank and 1000 Genome Project databases, respectively. EGFR Q787Q polymorphism had significant protective effects on the overall survival of EGFR-mutant lung adenocarcinoma treated with EGFR TKIs (aHR =0.61, p=0.03). Our study demonstrated that EGFR Q787Q polymorphism is a germline variant in the general population. It is a protective predictor of overall survival in patients with stage IV EGFR-mutated lung adenocarcinoma treated with TKIs.

表皮生长因子受体（Epidermal Growth Factor Receptor，EGFR）Q787Q多态性在肺腺癌治疗中的患病率及其影响目前仍不明确。本研究回顾性分析了IV期肺腺癌患者，旨在评估EGFR Q787Q多态性的患病率及其对酪氨酸激酶抑制剂（Tyrosine Kinase Inhibitor，TKI）治疗效果的影响，共纳入333例受试者。EGFR Q787Q多态性在全部受试者、EGFR突变阴性组及EGFR突变阳性组中的患病率分别为38%、42%与35%。EGFR野生型患者中该多态性的患病率，分别显著高于台湾生物银行（Taiwan Biobank）与千人基因组计划（1000 Genome Project）数据库中的普通非癌人群。对于接受EGFR-TKI治疗的EGFR突变型肺腺癌患者，EGFR Q787Q多态性对总生存期具有显著保护作用（aHR=0.61，P=0.03）。本研究证实，EGFR Q787Q多态性为普通人群中的种系变异，其可作为接受TKI治疗的IV期EGFR突变型肺腺癌患者总生存期的保护性预测因子。